An observational study of oral tofacitinib, baricitinib, upadacitinib and systemic steroids in refractory vitiligo, Mendeley Supplements.

1. Supplemental Materials including: Supplementary Figure 1: The VASI score in four groups at month 0, 3, and 6. Supplementary Figure 2: The VASI improvement in four groups at month 0, 3, and 6. Supplementary Figure 3: Serum levels of CXCL10 and CCL20 in four groups at month 0, 3, and 6. Supplementary Figure 4: Clinical photographs using a wood light of 4 patients receiving different monotherapy during the follow-up. (T, tofacitinib; B, baricitinib; U, upadacitinib; S, steroids). 2.Supplemental Methods

1. 补充材料包含以下内容：
补充图1：四组受试者在第0、3、6个月时的VASI评分。
补充图2：四组受试者在第0、3、6个月时的VASI改善情况。
补充图3：四组受试者在第0、3、6个月时的血清CXCL10与CCL20水平。
补充图4：随访期间接受不同单一疗法的4例患者采用伍德灯（Wood light）拍摄的临床照片。（T：托法替布（tofacitinib）；B：巴瑞替尼（baricitinib）；U：乌帕替尼（upadacitinib）；S：糖皮质激素（steroids））
2. 补充方法